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1. Introduction 
The incidence of type 2 diabetes is increasing worldwide, resulting in large measure from 
the increasing prevalence of obesity (Yale, 2000). Diabetes mellitus is a pandemic disease 
and is one of the main threats to human health (Narayan, 2005). In 2003, 194 million people 
worldwide, ranging in age from 20 to 79 years, had diabetes. It is projected that this number 
will be increased by 72% to 333 million by 2025, and nearly 80% of these cases will be in the 
poorer industrialized countries (IDF, 2003). According to a 2005 US Government estimate, 
approximately 21 million people in the United States have diabetes (Gerich, 2005).  In 2002, 
diabetes was the sixth leading cause of death and had an estimated total cost of $132 billion 
(Hogan et al. 2003). Type 2 diabetes is a disease characterized by a dual defect: 1) by insulin 
resistance which prevents cells from using insulin properly, and 2) degrees of reduced 
pancreatic insulin secretion.  
In the local context, according to World Health Organisation (WHO, 2004), prevalence of 
Type 2 diabetes in Pakistan for the year 2000 was 5.2 million and for 2030 it would be 
around 13.8 million. A quarter of the population of Pakistan would be classified as 
overweight or obese with the use of Indo-Asian-specific BMI cutoff values. Jafar et al (2006) 
have reported that prevalence of overweight was 25% and obesity was 10% in a large 
population-based sample of people over the age of 15 years in Pakistan. On the age-specific 
prevalence of overweight and obesity, they found that more than 40% of women and 30% of 
men aged 35–54 years were classified as overweight or obese.  
It has been suggested in a variety of observational and epidemiological studies that physical 
activity may play a significant role in the prevention of type 2 diabetes mellitus. The 
relationships between physical activity and overweight are only beginning to be understood 
for the adult population, sedentary behaviours, particularly watching television (TV) and 
videos, surfing the internet have been found to be related to higher body mass index 
(BMI) for adult’s population (Struber, 2004). The literature linking physical activity levels 
with risk of overweight in adults is not consistent but physical activity is an 
important component of effective obesity treatments (Saelens, 2003).  
The main health promotion intervention here is the public health education which 
highlights the importance of physical activity for the prevention of type 2 diabetes in the 
www.intechopen.com
 Medical Complications of Type 2 Diabetes 
 
394 
middle-aged population of sub-continent and particularly Pakistan, which is experiencing a 
rapid and substantial decline of physical activity levels as a result of poor eating habits, 
unhealthy food supply, expansion of television, computerization, and mechanization, more 
prevalent car ownership and sedentary behaviour. In parallel with decreasing levels of 
physical activity, the prevalence of overweight and obesity has increased significantly in 
Pakistan and as a consequence, diabetes mellitus has become a major public health issue.  
Therefore, promoting an active lifestyle or regular exercise has become the highest public 
health priority in that country to overcome the onslaught of type 2 diabetes. Also, the search 
for dietary adjuncts along with usual medical care to treat this life altering disease has 
become more important and dietary supplements that can modulate glucose homeostasis 
and potentially improve lipid parameters would be desirable. Fenugreek (Trigonella 
foenum-graecum Linn) is a dietary supplement that may hold promise in this regard and is 
one of the oldest medicinal plants, originating in India and Northern Africa and dating back 
to ancient Egyptian times (Jensen, 1992). 
In Pakistan and India, fenugreek is commonly consumed as a condiment (Yoshikawa et al. 
1997) and used medicinally as a lactation stimulant (Patil et al. 1997). Fenugreek seeds also 
lower serum triglycerides, total cholesterol (TC), and low-density lipoprotein cholesterol 
(LDL-C) (Al-Habori and Raman, 1998). The lipid-lowering effect of fenugreek might also be 
attributed to its estrogenic constituent, indirectly increasing thyroid hormones (Basch, 2003). 
The plant protein in fenugreek is 26%, so it might exert a lipid lowering effect (Sharma, 
1986). Since a high proportion of diabetic patients in sub-continent suffer from malnutrition, 
the use of fenugreek which is rich in protein and fiber (48%), has a distinct advantage in 
these patients (Sharma, 1986).     
This chapter addresses the effectiveness of fenugreek for lowering hemoglobin (HbA1c) in 
this randomized controlled trial and determines whether the intervention of taking 
fenugreek in combination of usual medical care lowers HbA1c in patients with type 2 
diabetes. Effectiveness trials such as this are critical in determining if the interventions are 
effective in the practical world in which patients live. This randomized control trial 
addresses the research question “Is Fenugreek treatment with medical care for patients 
with type 2 diabetes more effective than usual medical care and can it help to lower the 
haemoglobin in patients with poorly controlled type 2 diabetes”? and test the hypothesis 
in relation to type 2 diabetic patients with usual medical care and usual medical care with 
self-management of fenugreek supplement and evaluates the effectiveness of the fenugreek 
treatment in comparison with the usual medical care in clinical settings. 
2. Characteristics of type 2 diabetes 
Type 2 diabetes is associated with certain ethnic groups, obesity, family history of diabetes, 
and physical inactivity, among other factors. Diabetes is a metabolic disease characterized 
by elevated concentrations of blood glucose for prolonged periods of time, i.e., 
hyperglycemia (Gerich, 2005). Chronic, untreated hyperglycemia can lead to serious 
complications that include cardiovascular diseases, blindness, kidney failure, and stroke. 
Furthermore, very low values of blood glucose (hypoglycemia) for even a short duration can 
result in loss of consciousness and coma. The figure 1 shows the complications of type 2 
diabetes which is a syndrome characterized by insulin deficiency, insulin resistance, and 
increased hepatic glucose production. These metabolic abnormalities are treated by use of 
various medications which are designed to correct one or more of these metabolic 
abnormalities (Saltiel & Olefsky, 2001).  
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Type 2 diabetes is most common in adults, although younger people are also developing this 
type of disease. It starts with a slow onset with thirst, frequent urination, weight loss 
developing over weeks to months. It is also considered to run in families but it may happen 
with a person without a family history of diabetes as well. Most of the people who get this 
disease are overweight and obese. The treatment for type 2 diabetes differs at various stages of 
the condition. In its early stages, many people with type 2 diabetes can control their blood 
glucose levels by losing weight, eating properly and exercising. Many may subsequently need 
oral medication, and some people with type 2 diabetes may eventually need insulin shots to 
control their diabetes and avoid the disease's serious complications (Saltiel & Olefsky, 2001).  
Even though there is no cure for diabetes, proper treatment and glucose control enable 
people with type 2 diabetes to live normal, productive lives. A major advance for people at 
risk of developing type 2 diabetes - such as family members of those with the condition - 
occurred recently when it was shown that diet and exercise can prevent or delay type 2 
diabetes. People at high risk, who already had early signs of impaired glucose tolerance, 
significantly reduced their risk by losing only 5-7 percent of their body weight and 
performing moderate physical activity for 30 minutes/day.  
 
Diabetic
Retinopathy
Leading cause
of blindness
in adults
Diabetic
Nephropathy
Leading cause of 
end-stage renal disease
Cardiovascular
Disease
Stroke
2- to 4-fold increase in 
cardiovascular 
mortality and stroke
Diabetic
Neuropathy
Leading cause of
non-traumatic lower 
extremity amputations
8/10 individuals with 
diabetes die from CV 
events
 
Fig. 1. Complications of type 2 diabetes – Source: Saltiel & Olefsky (2001) 
The figure 1 shows the complications of type 2 diabetes from microvascular and 
macrovascular diseases and can have a devastating effect on quality of life and impose a 
heavy burden on healthcare systems. 
Diabetic retinopathy is present in 21% of people in the world at the time type 2 diabetes is 
diagnosed (DSG, 1990), more than 60% have diabetes retinopathy during the first two 
decades of the disease and diabetic retinopathy is the leading cause of new blindness among 
www.intechopen.com
 Medical Complications of Type 2 Diabetes 
 
396 
adults aged 20–74 years (Fong et al. 2003). Pakistan is ranked 6th among countries with the 
highest burden of diabetes (Wild et al. 2004), however, population-based data on the 
prevalence of diabetic retinopathy in Pakistan and on the visual impairment due to diabetic 
retinopathy is lacking and only the hospital-based data is available (Kayani et al. 2003).    
Diabetic nephropathy is present in 18% of people diagnosed with diabetes (DSG, 1993) and 
is a leading cause of end-stage renal disease (Molitch et al. 2003) 
Stroke: diabetes is associated with a 2- to 4-fold increase in cardiovascular mortality and 
stroke (Kannel et al. 1990). 
Cardiovascular disease: 75% of individuals with type 2 diabetes die from cardiovascular 
causes (Gray & Yudkin, 1997). 
Diabetic neuropathy is present in 12% of people at diagnosis (DSG, 1990) and diabetic 
neuropathy affects approximately 70% of people with diabetes and is a leading cause of non-
traumatic lower extremity amputations (Mayfield et al. 2003). Therefore, early detection and 
treatment of diabetes is essential in order to reduce the impact of its serious complications.  
2.1 Development of type 2 diabetes 
Development of type 2 diabetes is the result of multifactorial influences that include 
lifestyle, environment and genetics. The disease arises when insulin resistance-induced 
compensatory insulin secretion is exhausted. A high-caloric diet coupled with a sedentary 
lifestyle is one of the major contributing factors in the development of the insulin resistance 
and pancreatic ǃ-cell dysfunction as shown in Figure 2. However, a predisposing genetic 
background has long been suspected in playing a contributing role in the development of 
type 2 diabetes. By using whole-genome linkage analysis the entire genome of affected 
family members can be scanned and the family members monitored over several 
generations (Saltiel & Olefsky, 1996) 
 
 
Fig. 2. Development of type 2 diabetes: Adapted from Saltiel & Olefsky (1996) 
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Although the metabolic syndrome is not exclusively associated with type 2 diabetes and the 
associated insulin resistance, the increasing prevalence of obesity and associated 
development of type 2 diabetes places insulin resistance as a major contributor to the 
syndrome. The metabolic syndrome is defined as a clustering of atherosclerotic 
cardiovascular disease risk factors that include visceral adiposity (obesity), insulin 
resistance, low levels of HDLs and a systemic proinflammatory state. There are key 
components to the metabolic syndrome which include in addition to insulin resistance (the 
hallmark feature of the syndrome), hypertension, dyslipidemia, chronic inflammation, 
impaired fibrinolysis, procoagulation and most telling central obesity. 
3. Randomized controlled trials with fenugreek 
The multiple trials in the past have shown conflicting results of the effect of fenugreek on 
the patients of type 2 diabetes. These studies showed some positive results on fasting 
serum glucose but did not examine hemoglobin (HbA1c) levels. Gupta et al (2001) 
reported the results of a small randomized, controlled, double-blind trial to evaluate the 
effects of fenugreek seeds on glycemic control. The authors reported that there were no 
significant differences between groups in mean glucose tolerance test values at the 
study's end. This study suggested that fenugreek seed extract and diet/exercise may be 
equally effective strategies for attaining glycemic control in type 2 diabetes. However, 
the trial may have been too small or brief to detect significant mean differences between 
groups.  
Raghuram et al (1994) reported the results of a randomized, controlled, crossover trial of 
fenugreek seeds in 10 patients with type 2 diabetes. In the fenugreek-treated patients, 
statistically significant mean improvements were reported for glucose-tolerance test scores 
and serum-clearance rates of glucose. The absolute difference in glucose between the two 
groups was not mentioned. Sharma and Raghuram (1990) conducted two randomized, 
controlled, crossover studies in patients with type 2 diabetes. Significant mean 
improvements in fasting blood-glucose levels and glucose-tolerance test results were 
described in the fenugreek-treated patients.  
Moosa et al (2006) conducted study to evaluate the effect of fenugreek on serum lipid profile 
in hypercholesteremic type 2 diabetic patients and concluded that fenugreek seeds powder 
significantly reduced serum total cholesterol, triglyceride and LDL-cholesterol but serum 
HDL-cholesterol level elevation was not significant. Neeraja and Rajyalakshmi (1996) 
presented a case series including six men with type 2 diabetes and six without diabetes. The 
cases suggested fenugreek reduced postprandial hyperglycemia primarily in subjects with 
diabetes, but less so in subjects without diabetes.  
The results from several additional case series (Madar et al. 1988; Sharma, 1986; Sharma et 
al. 1996) also reported that fenugreek seeds may improve glycemic control in type 2 
diabetes. The studies conducted to date have been methodologically weak, lacking 
adequate descriptions of blinding, randomization, baseline patient characteristics, 
statistical analysis, and standardization data for the therapy used. Demonstrating the 
efficacy of fenugreek has also been confounded by inconsistencies in the preparations, 
dosing regimens, and outcome measures used in the trials. Moreover, none of the 
investigations have been conducted over the longer period (Basch, 2003). The following 
table 1 gives the summary of Randomized Controlled Trials evaluating fenugreek use in 
diabetic patients. 
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Authors Study Type Condition 
Sample 
size 
Results 
Gupta (2001) 
Randomized 
Controlled Trials  
(Double-blinded) 
Type 2 diabetes 
(hyperlipidemia) 
N =25 
Improved fasting 
glucose with 
fenugreek seeds and 
diet/exercise. 
Raghuram 
(1994) 
Randomized 
Controlled Trials 
(crossover study) 
Type 2 diabetes N =10 
Improved peripheral 
glucose utilization 
with  fenugreek seed 
supplementation 
Sharma (1990) 
Randomized 
Controlled Trials 
(crossover study 
Type 2 diabetes N =25 
Improvement in 
reported diabetic 
symptoms 
Neeraja (1996) 
Case series with 
matched controls 
Type 2 diabetes N =12 
Improvement of acute 
glycemic response 
with raw fenugreek 
seed powder 
Moosa et al 
(2006) 
Randomized 
Controlled Trials 
Type 2 diabetes 
(hyperlipidemia) 
N =30 
Reduced serum total 
cholesterol with the 
use of  fenugreek 
Table 1. Summary of Randomized Controlled Trials evaluating the use of fenugreek in 
diabetes 
4. Method of patient selection 
The patients were recruited from the diabetic medical centre in rural area of Peshawar 
conducting the study of management of type 2 diabetes among the population aged 30-65 
years.  The patients were eligible and subjected to further screening if their records were 
found in the clinic database as patients with diabetes and had HbA1c >= 7.0% on a 
laboratory blood test during the last 6 months. Patients having coexisting liver, kidney or 
thyroid disorder were not included in the study. Also, the patients with allergy to fenugreek 
were excluded from the study. 
The Word Health Organization (WHO, 2006) diabetes criteria were followed in the selection 
of the patients with diabetes as indicated in Table 2. 
 
Condition 2 hour glucose Fasting glucose 
 mmol/l(mg/dl) mmol/l(mg/dl) 
Normal <7.8 (<140) <6.1 (<110) 
Impaired fasting 
glycaemia 
<7.8 (<140) ≥ 6.1(≥110) & <7.0(<126) 
Impaired glucose 
tolerance 
≥7.8 (≥140) <7.0 (<126) 
Diabetes mellitus ≥11.1 (≥200) ≥7.0 (≥126) 
Table 2. World Health Organization (WHO, 2006). Diabetes Criteria for patients 
www.intechopen.com
Effectiveness of Fenugreek for Lowering Hemoglobin (HbA1c)  
in Patients with Self-Management of Type 2 Diabetes: A Randomized Controlled Trial 
 
399 
The well known standard screening test for diabetes, the fasting plasma glucose (FPG), is 
also a component of diagnostic testing. The FPG test and the 75-g oral glucose tolerance test 
(OGTT) are both suitable tests for diabetes; however, the FPG test is preferred in clinical 
settings because it is easier and faster to perform, more convenient and acceptable to 
patients, and less expensive. This test was carried out and an FPG ≥126 mg/dl (7.0 mmol/l) 
considered being an indication for retesting, which was repeated on a different day to 
confirm a diagnosis. If the FPG is <126 mg/dl (7.0 mmol/l) and there is a high suspicion for 
diabetes, an OGTT was performed. A 2-h postload value in the OGTT ≥200 mg/dl (11.1 
mmol/l) is a positive test for diabetes and was confirmed on an alternate day.  
When it was found necessary, plasma glucose testing was also performed on individuals 
who have taken food or drink shortly before testing. Such tests are referred to as casual 
plasma glucose measurements and are given without regard to time of last meal. A casual 
plasma glucose level ≥200 mg/dl (11.1 mmol/l) with symptoms of diabetes is considered 
diagnostic of diabetes. A confirmatory FPG test or OGTT was also completed on such 
patients on a different day if the clinical condition of the patient permits.  
Laboratory measurement of plasma glucose concentration is performed on venous samples 
with enzymatic assay techniques, and the above-mentioned values are based on the use of 
such methods. The A1C test values remain a valuable tool for monitoring glycemia, but it is 
not currently recommended for the screening or diagnosis of diabetes. Pencil and paper 
tests, such as the American Diabetes Association’s risk test, may be useful for educational 
purposes but do not perform well as stand-alone tests. Capillary blood glucose testing using 
a reflectance blood glucose meter has also been used but because of the imprecision of this 
method, it is better used for self-monitoring rather than as a screening tool.  
5. Determination of study sample size  
The study sample size was determined based on the assumption of the estimation of 
Standard Deviation (SD). Therefore, the study design was selected to detect an effect size of 
0.5 SD lowering of HbA1c. It was assumed that 15% patients might be lost to follow-up in 
control group over the period of three months and only 5 % patients will be lost to follow-
up in intervention group. This assumption was based on the popularity of fenugreek seeds 
used by diabetic patients in sub-continent to manage their glycemic control. Taking into 
consideration all these factors, the following parameters were considered: ǂ = Level of 
significance test = 0.05, Power = 0.8, m= the follow-up period 90 days (3 months), Standard 
Deviation (SD) = 0.5, the sample size was calculated for each group to detect an effect size of 
0.5 SD. The sample size (N) for each group was =105; therefore, the total, N=210 patients 
were recruited to participate in both the groups. 
6. Study population and randomization 
Initially 325 patients with type 2 diabetes were invited to pre-randomized interview, out of 
which only 210 patients were included in the actual trial. Out of the 325 patients, 93 patients 
did not meet the inclusion criteria and 22 patients refused to participate in the trial. Finally, 
two hundred and ten (210) patients agreed to participate and signed informed consent 
documents at the clinic where they used to visit for their usual medical care for diabetes. 
Therefore, 102 patients were randomized to intervention group (fenugreek supplements) 
and 108 to the control group (usual medical care). Figure 3 shows their progress during the 
randomized controlled trial. 
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Fig. 3. Flow chart describing Randomized Controlled Trial of fenugreek treatment:  
The sequence of allocation to treatments (a randomized list) was generated using the 
random number function in Excel worksheet. The baseline assessment was carried out 
prior to group allocation by an investigator/coordinator blind to the allocation sequence. 
The participants were issued a sealed envelope containing their group allocation. The 
randomization code was developed using a computer random number generator in a 
block size of eight patients. That helped to allocate patients to the intervention and control 
groups equally in each block – that is each patient would have an equal chance of 
allocation to either group. Once the randomization phase was completed, all patients 
were instructed to follow-up the usual medical care for their diabetes for the duration of 
the 90 days trial. The patients were allowed to adjust their usual medications as 
recommended by their doctors. In addition, each patient was asked to go for blood test for 
HbA1c on day 1 and then return to give blood sample after 90 days. In addition, 
participants were advised not to take any other new treatments for the management of 
type 2 diabetes during the trial periods.    
The control group in randomized controlled trial received medical care from a physician-
coordinated team. This team included physicians, nurses, dietitians, and mental health 
professionals with expertise and a special interest in diabetes. It is essential in this collaborative 
and integrated team approach that individuals with diabetes assume an active role in their 
care. The management plan in that group was based on individualized therapeutic alliance 
among the patient and family, the physician, and other members of the health care team. This 
plan has recognized diabetes self-management education as an integral component of care and 
Patients with type 2 diabetes invited to 
pre-randomized interview  
(n= 325) 
Randomisation (n = 210) 
Control group (n=108) 
      (usual medical Care) 
Received allocated comparison 
    
Not randomized 
Not meeting inclusion criteria (n= 93) 
Refused to participate (n= 22) 
Intervention Group (n= 102) 
 (Fenugreek Treatment) 
Received allocated intervention  
Lost to follow-up/ withdrawn 
  (n = 16) – 15% 
Lost to follow-up/ withdrawn 
  (n = 5) – 5% 
Followed-up at 3 months (n = 97) Followed-up at 3 months (n = 92) 
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in developing the plan, consideration was given to the patient’s age, work schedule and 
conditions, physical activity, eating patterns, social situation and personality, cultural factors, 
and presence of complications of diabetes or other medical conditions. Treatment goals were 
set together with the patient, family, and health care team. Patient self-management was 
emphasized, and the plan emphasized the involvement of the patient in problem-solving as 
much as possible. A variety of strategies and techniques were employed to provide adequate 
education and development of problem-solving skills in the various aspects of diabetes 
management. During the implementation of the management plan it was assured that each 
aspect of diabetes management was understood and agreed on by the patient and the care 
providers and that the goals and treatment plan were reasonable.  
Those patients randomized to take fenugreek (intervention group) received 100 gms 
fenugreek seeds powder from the pharmacy in the clinic. They were instructed to take 50 
gms doses twice a day at lunch and dinner time in addition to their normal medications for 
diabetes. Those patients randomized to usual medical care (control group) were instructed 
to take their normal medicines and follow-up with their doctor as per their normal schedule. 
All participants were contacted again after 90 days (3-months) to give their blood sample for 
HbA1c testing. At that time, a questionnaire was sent via e-mail to participants in both 
intervention and control groups to assess the progress of the fenugreek treatment and 
clinical care without fenugreek.  
The clinical and demographic characteristics of the patients in the two groups were well 
balanced at randomization. A demographic measure included age, gender, weight, 
ethnicity, religion, marital status, previous episodes of glycemic control, previous and 
current treatments of type 2 diabetes.  The table 3 gives baseline characteristics of 
intervention and control groups in RCT trial.  
 
Characteristics 
Intervention Group 
(n = 97) 
Control Group 
(n = 92) 
P-value 
Age (years) 
Mean (62.5) ±   
SD (10.5) 
Mean (59.5) ±   
SD (8.5) 
0.78 
Sex 
Male 
Female 
 
56% (n = 54) 
44% (n = 43) 
 
58% (n = 53) 
42% (n = 39) 
 
Body Mass Index (Kg/m2) 
Mean (30.8) ±   
SD (6.5) 
Mean (31.6) ±   
SD (6.5) 
 
0.40 
Fenugreek Intake 
Normal 
High 
 
98% (n=95) 
2%   (n = 2) 
 
      - 
      - 
 
Baseline Hemoglobin  
(HbA1c) % 
Mean (8.5) ±   
SD (1.6) 
Mean (8.4) ±   
SD (1.5) 
0.59 
 
Diabetes Medications 
Mean (1.75) ±   
SD (0.8) 
Mean (1.82) ±   
SD (0.8) 
0.15 
Table 3. Baseline characteristics of intervention and control groups in RCT trial 
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7. Type 2 diabetes treatments 
7.1 Diabetes treatment with medications 
The treatment options of type 2 diabetes is shown in figure 4 suggesting the specific areas of 
actions using medications which influence the various organs of the body to correct the 
metabolic abnormalities such as reducing the liver glucose production, slowing down 
absorption of sugars from the gut and reducing the insulin resistance. There are currently 
six distinct classes of hypoglycemic agents available to treat type 2 diabetes. These agents 
are Sulfonylurea (gliclazide, glipizide etc) – increase insulin secretion; Meglitinide 
(repaglinide) – increase insulin secretion; Biguanides (metformin) – reduce glucose 
production; Alpha-glycosidase (acrobase) – slow down absorption of sugar from the gut; 
Thiazolidendiones (pioglitazone) – reduce insulin resistance and Incretins – increase insulin 
secretion.  
The patients in both the groups in RCT trials received medications recommended by their 
physicians. The most common combinations among both the groups were Meglitinide 
(repaglinide) with Thiazolidendiones and Sulfonylurea with Biguanides. However, the 
intervention group was given fenugreek as an additional supplement. The table 4 shows the 
hypoglycemic medications used by the patients during fenugreek RCT trial for 90 days. 
 
 
 
 
 
 
 
 
Fig. 4. Treatment options for type 2 diabetes – Source: Saltiel & Olefsky (2001) 
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Medication Doses Action 
Sulfonylurea (Gliclazide) 30-120 mg/day Increase insulin secretion 
Meglitinide (Repaglinide) 0.5-4 mg/meal Increase insulin secretion 
Biguanides (Metformin) 25-3000 mg/day 
Decrease hepatic glucose 
secretion 
Thiazolidendione (Glitazone) 15-30 mg/day 
Increase the insulin receptor 
number 
Fenugreek (only for patients in 
intervention group) 
100 gm/day Help to lower HbA1c 
Table 4. Hypoglycemic medications used by patients in fenugreek RCT trial 
7.1.1 Details of hypoglycaemic medications used in RCT trial 
The diabetes medications mentioned in table 4 work in different ways but the main function 
of all these medications include lowering blood sugar levels; help improve the body’s use of 
glucose, decrease the symptoms of high blood sugar, help keeping patients with diabetes 
functioning normally and may prevent the complications, organ-damaging effects and 
premature deaths diabetes can cause. Since the drugs work in different ways, these are 
sometimes used in combination to enhance the effectiveness of treatment. In this RCT trial 
Sulfonylurea was used in combination with Biguanide (metformin) and Meglitinide was 
used in combination with Thiazolidinedione. However, fenugreek supplementation was 
only given to the patients in intervention group. The advantages and disadvantages of these 
medications used in RCT trial are given in Table 5 and the details of their mode of actions 
are summarized as follows: 
Sulfonylurea: The sulfonylurea (Gliclazide) is an oral hypoglycemic drug and referred to as 
endogenous insulin secretagogues because the drug induces the pancreatic release of 
endogenous insulin. The fact that this drug induces pronounced hypoglycemia, treatment is 
initiated with the lowest possible dose and carefully monitored until the dose is found to 
control glucose level at 110-140mg/dL. The main function of Sulfonylurea is to bind and 
inhibit the pancreatic ATP-dependent potassium channel that is normally involved in 
glucose-mediated insulin secretion. Sulfonylurea has no significant effects on circulating 
triglycerides, lipoproteins or cholesterol. 
Meglitinide: The meglitinide (repaglinide) is a non-sulfonylurea insulin secretagogues that 
is both fast acting and of short duration. Like the sulfonylurea, meglitinide therapy results 
in significant reduction in fasting glucose as well as HbA1c. The mechanism of action of the 
meglitinide is initiated by binding to a receptor on the pancreatic ǃ-cell that is distinct from 
the receptors for the sulfonylurea. However, meglitinide do exerts effects on potassium 
conductance. Like the sulfonylurea, the meglitinide have no direct effects on the circulating 
levels of plasma lipids. 
Biguanide: The biguanide (metformin) is a class of drugs that function to lower serum 
glucose levels by enhancing insulin-mediated suppression of hepatic glucose production 
and enhancing insulin-stimulated glucose uptake by skeletal muscle. Metformin is a 
member of this class and is currently the most widely prescribed insulin-sensitizing drug in 
current clinical use. Metformin administration does not lead to increased insulin release 
from the pancreas and as such the risk of hypoglycemia is minimal. Because the major site of 
action for metformin is the liver its use can be contraindicated in patients with liver 
dysfunction. The drug is ideal for obese patients and for younger type 2 diabetics.  
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Thiazolidinedione: The thiazolidinedione (pioglitazone) has proven useful in treating the 
hyperglycemia associated with insulin-resistance in both type 2 diabetes and non-diabetic 
conditions. The net effect of the thiazolidinedione is a potentiation of the actions of insulin 
in liver, adipose tissue and skeletal muscle, increased peripheral glucose disposal and a 
decrease in glucose output by the liver.  
 
Medications Advantages Disadvantages 
Sulfonylurea (Gliclazide) 
Fast onset of action 
No effect on blood pressure 
No effect on LDL cholesterol 
Convenient dosing 
Low cost 
Weight gain reported 
Risk of hypoglycemia 
Meglitinide (Repaglinide) 
No bad effect on cholesterol 
Rapid onset of action 
Risk of hypoglycemia 
Weight gain reported 
Inconvenient dosing 
High cost 
Biguanides (Metformin) 
Low risk of hypoglycemia 
Not linked to weight gain 
Good effect on LDL 
cholesterol 
No ill effect on blood 
pressure 
Low cost 
High risk of GI side 
effects 
(nausea and diarrhea) 
Risk of lactic acid build-
up 
Less convenient dosing 
Thiazolidendione 
(Glitazone)  
Low risk of hypoglycemia 
Increase in HDL cholesterol 
Linked to decreased 
triglycerides 
Convenient dosing 
Higher risk of heart 
failure 
Linked to weight gain 
Linked to risk of edema 
Linked to risk of anemia 
Slower onset of action 
Increase in LDL 
cholesterol 
Table 5. Advantages and disadvantages of medications used by patients in fenugreek RCT 
trial 
7.2 Diabetes treatment with diet and exercise 
The normal diabetes treatment addresses the issues related to unhealthy lifestyles, such as 
lack of physical activity and excessive eating, which are the main causes to initiate and 
propagate the majority of type 2 diabetes (Michael, 2007). Studies have demonstrated strong 
relationship between excess weight and the risk of developing type 2 diabetes, 
hypertension, and hyperlipidemia.  Therefore, the objective of physicians is to motivate 
patients to lose weight and exercise to improve the control of diabetes and slow down or 
even reverse the natural course of the disease (Michael, 2007). 
However, it is difficult to overstate the importance of the relationship between lifestyle and 
the risk of developing type 2 diabetes. It has been demonstrated in recent studies that both 
women and men who have a BMI >35 kg/m2 had a 20-fold increase in their risk of 
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developing diabetes compared to people with a BMI of 18.5 – 24.9 kg/m2 (Mokdad et al. 
2001; Field et al. 2001). There are prospective studies which have demonstrated that lifestyle 
modification in the form of diet and regular moderate exercise sharply decrease the 
likelihood of developing type 2 diabetes in high-risk individuals who have impaired glucose 
tolerance or impaired fasting glucose. The effectiveness of this intervention superseded that 
of metformin therapy (Knowler et al. 2002).  In this RCT trial, physicians compiled the flow 
scheme shown in Figure 5 which represents the method of treatment of type 2 diabetes by 
the combination of diet, exercise and medication for diabetes monitoring and control. It has 
been divided into two segments: for obese and normal weight patients and the combination 
of medication for both the groups of patients. The supplement of fenugreek was given to the 
patients belonging to intervention group.  
 
Treatment of type 2 Diabetes
Diet / Exercise
Sulfonylurea 
or Meglitinide 
Combination ( Sulf + Met + Glit + Meg)
Obese Normal Weight
Metformin
or Glitazon
Fenugreek Supplement Intervention Group only
 
Fig. 5. Treatment of type 2 diabetes with the combination of diet, exercise and medications. 
7.2.1 Dietary consideration for patients (intervention and control group) 
It has been recommended that carbohydrate and monosaturated fat consumption for the 
patients with type 2 diabetes should comprise 60-70% of total calories. However, there is 
some concern that increased unsaturated fat consumption may promote weight gain in 
obese patients with type 2 diabetes and therefore may cause in reduction of insulin 
sensitivity (Bantle et al. 1993). The “glycemic index” is an attempt to compare the glycemic 
effects of various foods to a standard, such as white bread. Although several authors have 
proposed its clinical usefulness in controlling postprandial hyperglycemia, prospective 
studies have not demonstrated a clear improvement in hemoglobin (HbA1c) in patients 
using low-glycemic index diets (Michael, 2007).  
The physicians in this trial have recommended the best mix of carbohydrate, protein, and fat 
that was adjusted to meet the metabolic goals and individual preference of the patients with 
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diabetes in both the intervention and control groups. It has been recommended for 
individuals with diabetes, that the use of the glycemic index and glycemic load may provide 
a modest additional benefit for glycemic control over that observed when total carbohydrate 
is considered alone (ADA, 2011). Monitoring carbohydrate, whether by carbohydrate 
counting, choices, or experience-based estimation, remain a key strategy in achieving 
glycemic control. In addition, saturated fat intake should be less than 7% of total calories 
and the intake of trans fat should also be minimized. 
7.2.2 Physical activity consideration for patients (intervention and control group) 
Physical activity is a key component of lifestyle modification that can help individuals 
prevent or control type 2 diabetes. It is considered that diet  is probably more important in 
the initial phases of weight loss, incorporating exercise as part of a weight loss regimen 
helps maintain weight and prevent weight regain (Klein et al. 2004). In this trial, the 
message was given to both the groups that as little as 30 minutes of moderate physical 
activity daily may offer greater benefits to these patients  in managing their diabetes. It has 
also been reported that in patients with type 2 diabetes, structured regimens of physical 
activity for 8 weeks or longer improved HbA1c independent of changes in body mass (Sigal 
et al. 2006).  
The evidence supports the contention that controlling blood glucose through modification 
of diet and lifestyle should be mainstay of diabetes therapy. It was found in this RCT that 
despite being one of the most time-consuming discussions with the patients in both the 
groups, this is probably the most important patient-physician discussion in regard to 
diabetes control and prevention of disease progression and complications.    
8. Statistical analysis 
We analysed the primary outcome by an un-paired sample t-test (mean difference between 
baseline and final HbA1c). The statistical analysis was carried out on an intention to treat 
basis and that was subject to the availability of data at follow up as well as at entry level for 
individual patients. The differences between mean changes were tested by unpaired t tests, 
and χ2 tests (chi-squared test) were used to test for differences in proportions between the 
fenugreek treatment and clinical based treatment groups. For the χ2 tests, the following 
formula was used. 
2
2 (observed expected)
expected
  
  
In this study for example (using the data from Figure 3) – it shows that number of patients at 
three months follow-up who were allocated to intervention group to help lowering their 
glycemic control were 95 % as compared the patients in clinical care (85 %), so χ2 = 5.73, P=0.02). 
The association between the groups and outcome is considered statistically significant.  
All the patients in intervention and control groups were provided glucometers to check 
their blood sugar three times in a day (Fasting sugar in the morning, at bed time and 2-hrs 
after meal) and record that on XL-worksheet prepared for them to enter the data. Then 
linear regression analysis was performed after three months between HbA1c and on the 
blood glucose results. The HbA1c and the self-glucose monitoring via a glucometer 
demonstrated a significant relationship (R = .90, P < 0.0001).  
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These findings are in agreement with the findings of Nathan et al. (2008) who reported that 
the linear regression analysis carried out by these authors between the HbA1c and blood 
glucose (BG) values provided the tightest correlations (BG = 28.7 × A1C − 46.7, R2 = 0.84, P < 
0.0001), allowing calculation of an estimated average glucose for HbA1C values. The linear 
regression equations did not differ significantly across subgroups based on age, sex, 
diabetes type, race/ethnicity, or smoking status. 
9. Results and discussions  
The results of this randomized controlled trial support the hypothesis and research question 
that fenugreek supplement with usual medical care for type 2 diabetes is more effective than 
the usual medical care alone. The changes in HbA1c from baseline values in intervention 
and control groups after 3 months were calculated by unpaired sample t-test, the results are 
given in Table 6. At 3 months follow-up, the intervention group (fenugreek treatment) has 
shown significantly greater improvement and lowered HbA1c by 0.92% (95% CI, 0.34-1.50), 
p < 0.001 as compared with usual medical care alone lowering HbA1c by 0.42% (95% CI, 
0.11-0.94), p = 0.12 in patents with poorly controlled diabetes. 
The higher % age of lost to follow up throughout this trial (Figure 3) in those patients with 
usual medical care (15%) than in those treated by fenugreek (5%) suggests greater 
satisfaction with fenugreek supplement. The difference at 3 months follow up is the mean 
change for the intervention group minus the mean change for the control group. Therefore, 
the positive differences reflect more improvement in those treated by fenugreek supplement 
than in medical care alone. 
 
RCT 
(Groups) 
Baseline 
(HbA1c) 
Final 
(HbA1c) 
Difference 
P-
value 
Treatment (n=97) 
 
Control (n= 92) 
9.32 ± 2.2 
 
9.10 ± 2.1 
8.4 ± 1.9 
 
8.68 ± 1.6 
- 0.92 (95% CI, 0.34-1.50) 
 
- 0.42 (95% CI, 0.11- 0.94) 
< .001 
 
0.12 
Table 6. Effect of Fenugreek on Hemoglobin (HbA1c) in type 2 diabetes 
In patients with type 2 diabetes previous studies have shown an association between the 
degree of hyperglycemia and increased risk of microvascular complications (Klein, 1995), 
sensory neuropathy (Alder et al 1997), myocardial infarction (Klein, 1995; UKPDS,1998), 
stroke (Lehto et al. 1996), macrovascular mortality (Groeneveld et al. 1999) and all cause 
mortality (Wei et al. 1998; Knuiman et al. 1992). Generally, these studies measured glycemia 
as being high or low or assessed glycemia on a single occasion, whereas repeated 
measurements of glycemia over several moths or year would be more informative.  
The existence of thresholds of glycemia—that is, concentrations above which the risk of 
complications markedly increases was studied in patients with type 2 diabetes by Stratton et 
al. (2000). The relative risk for myocardial infarction seems to increase with any increase in 
glycemia above the normal range (Fuller et al. 1983) as shown in figure 6 whereas the risk 
for microvascular disease is thought to occur only with more extreme concentrations of 
glycemia (Krolewski et al. 1995). The diabetes control and complications trial (DCCT) 
research group showed an association between glycemia and the progression of 
microvascular complications in patients with diabetes for hemoglobin HbA1C over the 
range of 6-11% after a mean of six years of follow up (DCCT, 1996).  
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Source: Diabetic Control and Complications Trials (DCCT, 1996; Stratton et al. 2000) 
Fig. 6. Relative risk of progression of diabetic complications by mean HbA1c 
It has been reported by Stratton et al (2000) that the incidence of clinical complications was 
significantly associated with glycemia. That is each 1% reduction in updated mean HbA1c 
was associated with reductions in risk of 21% for any end point related to diabetes (95% 
confidence interval 17% to 24%, P<0.0001), 21% for deaths related to diabetes (15% to 27%, 
P<0.0001), 14% for myocardial infarction (8% to 21%, P<0.0001), and 37% for microvascular 
complications (33% to 41%, P<0.0001). The current fenugreek trial has demonstrated that 
there is a significant improvement after 3 months follow-up in the intervention group 
(fenugreek treatment) which has lowered HbA1c by 0.92% (95% CI, 0.34-1.50), p < 0.001 as 
compared to medical care alone lowering HbA1c by 0.42% (95% CI, 0.11-0.94), p = 0.12 in 
patents with poorly controlled diabetes. These finding are in agreement with the studies by 
Stratton et al (2000)  that any reduction in HbA1c is likely to reduce the risk of 
complications, with the lowest risk being in those with HbA1c values in the normal range (< 
6.0%). 
10. Strength and weakness of the study  
The strength of this trial is that it was an effectiveness trial that addressed the community 
clinical practice specific to the population in sub-continent and it has measured outcomes 
that are most significant to diabetes care providers. Previous trials have shown conflicting 
results about the efficacy of fenugreek to treat diabetes as summarized in Table 1 and none 
of the trials measured HbA1c as an outcome in their studies. There are several reasons of the 
success of this trial as compared to previous trials. The first reason is that this is the largest 
randomized fenugreek trial (n =210) to date in type 2 diabetes. The other reason is that we 
studied only patients with poorly controlled type 2 diabetes and finally, diabetics in sub-
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continent may have different characteristics than those in other western countries due to 
their eating of different foods and drinking habits.   
It is possible that the outcome measures associated with fenugreek treatment are subject to 
bias particularly when treatment was in progress or just afterwards. The main difference 
between usual medical care alone for the patients and usual medical care with fenugreek 
treatment occurred after 3 months period of trial. In order to reduce the bias, the 
questionnaire was sent to patients at home or via e-mail to minimize any chance that their 
answers might be affected by actual or perceived influence by medical practitioners at clinic. 
Also, the doctors did not know about those patients who were using fenugreek supplement 
and were blinded to the treatment allocation.  
11. Contribution of the trial to public health 
The main contribution of this study is to provide health professionals (diabetes care providers) 
and patients with type 2 diabetes an easily available, safe and cheap alternative (fenugreek 
seeds powder) to help them in the self-management and treatment of type 2 diabetes. The 
United Kingdom Prospective Diabetes Study (UKPDS) reported that a reduction of HbA1c 
from 7.9% to 7% lowers the risk of macro-vascular disease by 16%, retinopathy by 17% to 21% 
and nephropathy by 24% to 33% (UKPDS, 1998). Therefore, the results of this trial which have 
shown improvement in patients of diabetes by lowering HbA1c by 0.92% (95% CI, 0.34-1.50) 
might be expected to provide similar reductions in morbidity. 
12. Future research 
The use of fenugreek as a dietary supplement hold promise in future to be used in patients 
who manifest abnormalities of glucose monitoring and could benefit from a low-risk, 
inexpensive, food-based intervention aimed at normalizing their blood sugar levels and 
more specifically the HbA1c targets. However, the data collected to date on the benefits of 
fenugreek are sparse but may be used in future research for the development of well-
designed, adequately powered, large scale randomized clinical trials for evaluating the 
effect of fenugreek seed powder on measures of insulin resistance, insulin secretion and 
better glucose control among the patients with type 2 diabetes. 
13. Conclusion  
In this randomized controlled trial, it has been shown that the levels of HbA1c reduced in the 
patients of poorly controlled type 2 diabetes who were taking 50 gms doses of fenugreek twice 
a day in addition to their normal medications for diabetes. These results of RCT support the 
hypothesis and the research question that fenugreek supplement with usual medical care for 
type 2 diabetes is more effective than the usual medical care alone. Therefore, it is 
recommended that fenugreek supplementation is safe and may be considered in patients with 
HBA1c > 7% as a potential means to lower the high levels of HbA1c.  
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